期刊文献+

小肠低分化神经内分泌癌的诊断与治疗 被引量:2

Diagnosis and treatment of poorly differentiated small intes- tinal neuroendocrine carcinoma
原文传递
导出
摘要 小肠神经内分泌癌是一类起源于弥散性神经内分泌系统的低分化高度恶性肿瘤,弥漫性表达神经内分泌分化的一般性标志物。该病表现为类癌综合征,但大多数患者起病隐匿且缺乏特异性临床表现,术前诊断较困难。2012年6月18日江苏省苏北人民医院收治1例因接受胶囊内镜检查导致胶囊滞留引起肠梗阻的患者。患者经手术治疗解除肠梗阻症状,术中发现远端小肠恶性病变,术后病理检查结果证实为回肠低分化神经内分泌癌伴转移。 Small intestinal neuroendocrine carcinoma is poorly differentiated, highly malignant, and originated from the diffuse neuroendocrine system. It diffusely expresses the general neuroendocrine differentiation markers. The disease can be manifested as carcinoid syndrome, but most of the patients were with occult onset and absence of specific clinical symptoms, which led to difficult diagnosis before operation. On June 18, 2012, a patient with manifestation of recurrent vague abdominal pain received capsule endoscopy at the Northern Jiangsu People's Hospital. The capsule endoscope was retained in the distal small intestine, and malignant ileum lesion was revealed during the surgical exploration. Finally, poorly differentiated neuroendocrine carcinoma with abdominal wall metastases was identified by pathological examination.
出处 《中华消化外科杂志》 CAS CSCD 北大核心 2013年第10期804-806,共3页 Chinese Journal of Digestive Surgery
基金 国家自然科学基金青年科学基金项目(81300721)
关键词 神经内分泌肿瘤 小肠肿瘤 Neuroendocrine neoplasm Small intes-tinal neoplasms
  • 相关文献

参考文献8

  • 1龚加庆,田伏洲,曹永宽,张国虎,王培红,张林.小肠出血的检查方法和手术时机[J].中华消化外科杂志,2011,10(3):222-222. 被引量:2
  • 2Liao L, Gao R, Xu C, et al. Indications and detection, comple- tion, and retention rates of small-bowel capsule endoscopy: a sys- tematic review. Gastrointest Endosc,2010,71 (2) :280-286.
  • 3Plckinger U, Rindi G, Arnold R, et al. Guidelines for the diag- nosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society ( ENETS ). Neuroendocrinology, 2004,80 ( 6 ) : 394-424.
  • 4Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocne tumor epidemiology: contrasting Norway and North America. Cancer, 2008,113 ( 10 ) :2655-2664.
  • 5Kerstrm G, Hellman P, Hessman O. Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroen- terol,2005,19 (5) :717-728.
  • 6中国胃肠胰神经内分泌肿瘤病理学诊断共识[J].中华病理学杂志,2011,40(4):257-262. 被引量:291
  • 7Turaga KK, Kvols LK. Recent progress in the understanding, di- agnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin,2011,61 (2) : 113-132.
  • 8Yao JC, Hassan M, Phan A, et al. One hundred years after "car- cinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin 0ncol,2008, 26(18) :3063-3072.

二级参考文献13

  • 1Yaov JC,Hassan M,Phan A,et al.One hundred years after "carcinoid ":epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.J Clin Oncol,2008,26(18):3063-3072.
  • 2Yao JC,Shah MH,Ito T,et al.Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med,2011,364(6):514-523.
  • 3Raymond E,Dahan L,Raoul JL,et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.N Engl J Med,2011,36(6):501-513.
  • 4Kl(o)ppel G,Couvelard A,Perren A,et al.ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification.Neuroendocrinology,2009,90 (2):162-166.
  • 5Klimstra DS,Modlin IR,Adsay NV,et al.Pathology reporting of neuroendocrine tumors:application of the Delphic consensus process to the development of a minimum pathology data set.Am J Surg Pathol,2010,34(3):300-313.
  • 6Bosman FT,Carneiro F,Hruban RH,et al.WHO classification of tumours of the digestive system.Lyon:IARC Press,2010.
  • 7Oberndorfer S.Karzinoide tumoren des dunndarms.Frankf ZPatrol,1907,1:426-432.
  • 8Williams ED,Siebenmann RE,Sobin LH.Histological typing of endocrine tumours.Geneva:World Health Organization,1980.
  • 9Hamilton SR,Aaltonen LA.World Health Organization classification of tumours.Pathology and genetics of tumours of the digestive system.Lyon:IARC Press,2000.
  • 10Rindi G,Kl(o)ppel G,Alhman H,et al.TNM staging of foregut (neuro) endocrine tumors:a consensus proposal including a grading system.Virchows Arch,2006,449(4):395-401.

共引文献291

同被引文献48

  • 1Modlin IM,Oberg K,Chung DC,et al.Gastroenteropancreatic neuroendocrine tumours[J].Lancet Oncol,2008,9(1):61-72.
  • 2Oberg K.Neuroendocrine tumors (NETs):historical overview and epidemiology[J].Tumori,2010,96(5):797-801.
  • 3Ito T,Igarashi H,Nakamura K,et al.Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan:a nationwide survey analysis[J].J Gastroenterol,2014.[Epub ahead of print].
  • 4Niederle MB,Niederle B.Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors:current data on a prospectively collected,retrospectively analyzed clinical multicenter investigation[J].Oncologist,2011,16(5):602-613.
  • 5Korse CM,Taal BG,Vincent A,et al.Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade.A marker study of Chromogranin A,Neuron specific enolase,Progastrin-releasing peptide and cytokeratin fragments[J].Eur J Cancer,2012,48(5):662-671.
  • 6Modlin IM,Gustafsson BI,Moss SF,et al.Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease[J].Ann Surg Oncol,2010,17(9):2427-2443.
  • 7Alexandraki KI,Kaltsas G.Gastroenteropancreatic neuroendocrine tumors:new insights in the diagnosis and therapy[J].Endocrine,2012,41(1):40-52.
  • 8Arnold R,Wilke A,Rinke A,et al.Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors[J].Clin Gastroenterol Hepatol,2008,6 (7):820-827.
  • 9Massironi S,Conte D,Sciola V,et al.Plasma chromogranin A response to octreotide test:prognostic value for clinical outcome in endocrine digestive tumors[J].Am J Gastroenterol,2010,105(9):2072-2078.
  • 10Yao JC,Pavel M,Phan AT,et al.Chromogranin A and neuronspecific enolase as prognostic markers in patients with advanced pNET treated with everolimus[J].J Clin Endocrinol Metab,2011,96(12):3741-3749.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部